Briefing From The Editor -- ZTS Stock

By Naomi Wentworth • Wednesday, December 03 10:10 • Permanent Link

Zoetis logged a 0.0% change during today's morning session, and is now trading at a price of $124.5 per share. The S&P 500 index moved -0.0%. ZTS's trading volume is 496,000 compared to the stock's average volume of 3,762,182.

Zoetis trades -26.75% away from its average analyst target price of $169.96 per share. The 15 analysts following the stock have set target prices ranging from $130.0 to $200.0, and on average have given Zoetis a rating of buy.

If you are considering an investment in ZTS, you'll want to know the following:

Zoetis's current price is 246.5% above its Graham number of $35.93, which implies that at its current valuation it does not offer a margin of safety
Zoetis has moved -29.0% over the last year, and the S&P 500 logged a change of 12.2%
Based on its trailing earnings per share of 5.94, Zoetis has a trailing 12 month Price to Earnings (P/E) ratio of 21.0 while the S&P 500 average is None
ZTS has a forward P/E ratio of 19.6 based on its forward 12 month price to earnings (EPS) of $6.34 per share
Its Price to Book (P/B) ratio is 10.18 compared to its sector average of None
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally.
Based in Parsippany, the company has 13,800 full time employees and a market cap of $55.18 Billion. Zoetis currently returns an annual dividend yield of 1.6%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.